This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Tarn C , Merkel E , Canutescu AA , Shen W , Skorobogatko Y , Heslin MJ , Eisenberg B , Birbe R , Patchefsky A , Dunbrack R , Arnoletti JP , Von Mehren M , Godwin AK
Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: Therapeutic implications through protein modeling
Clinical Cancer Research. 2005 ;11(10) :3668-3677
AbstractPurpose: Gastrointestinal stromal tumors (GIST) are characterized by expressing a gain-of-function mutation in KIT, and to a lesser extent, PDGFR. Imatinib mesylate, a tyrosine kinase inhibitor, has activity against GISTs that contain oncogenic mutations of KIT. In this study, KIT and PDGFR? mutation status was analyzed and protein modeling approaches were used to assess the potential effect of KIT mutations in response to imatinib therapy. Experimental Design: Genomic DNA was isolated from GIST tumors. Exons 9, 11, 13, and 17 of c-KIT and exons 12, 14, and 18 of PDGFR? were evaluated for oncogenic mutations. Protein modeling was used to assess mutations within the juxtamembrane region and the kinase domain of KIT. Results: Mutations in KIT exons 9, 11, and 13 were identified in GISTs with the majority of changes involving the juxtamembrane region of KIT. Molecular modeling indicates that mutations in this region result in disruption of the KIT autoinhibited conformation, and lead to gain-of-function activation of the kinase. Furthermore, a novel germ-line mutation in KIT was identified that is associated with an autosomal dominant predisposition to the development of GIST. Conclusions: We have used proteih modeling and structural analyses to elucidate why patients with GIST tumors containing exon 11 mutations are the most responsive to imatinib mesylate treatment. Importantly, mutations detected in this exon and others displayed constitutive activation of KIT. Furthermore, we have found tumors that are both KIT and PDGFR? mutation negative, suggesting that additional, yet unidentified, abnormalities may contribute to GIST tumorigenesis. © 2005 American Association for Cancer Research.
Notes10780432 (ISSN) Cited By: 3; Export Date: 25 May 2006; Source: Scopus CODEN: CCREF Language of Original Document: English Correspondence Address: Godwin, A.K.; Department of Medical Oncology; Fox Chase Cancer Center; 333 Cottman Avenue Philadelphia, PA 19111, United States; email: Andrew.Godwin@fccc.edu Chemicals/CAS: imatinib, 152459-95-5, 220127-57-1 References: Mazur, M.T., Clark, H.B., Gastric stromal tumors. Reappraisal of histogenesis (1983) Am J Surg Pathol, 7, pp. 507-519; Sircar, K., Hewlett, B.R., Huizinga, J.D., Chorneyko, K., Berezin, I., Riddell, R.H., Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors (1999) Am J Surg Pathol, 23, pp. 377-389; Kindblom, L.G., Remotti, H.E., Aldenborg, F., Meis-Kindblom, J.M., Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal (1998) Am J Pathol, 152, pp. 1259-1269; Sarlomo-Rikala, M., Kovatich, A.J., Barusevicius, A., Miettinen, M., CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34 (1998) Mod Pathol, 11, pp. 728-734; Besmer, P., Murphy, J.E., George, P.C., A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family (1986) Nature, 320, pp. 415-421; Yarden, Y., Kuang, W.J., Yang-Feng, T., Human protooncogene c-kit: A new cell surface receptor tyrosine kinase for an unidentified ligand (1987) EMBO J, 6, pp. 3341-3351; Claesson-Welsh, L., Eriksson, A., Westermark, B., Heldin, C.H., cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor (1989) Proc Natl Acad Sci U S A, 86, pp. 4917-4921; Yarden, Y., Escobedo, J.A., Kuang, W.J., Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors (1986) Nature, 323, pp. 226-232; Coussens, L., Van Beveren, C., Smith, D., Structural alteration of viral homologue of receptor protooncogene fms at carboxyl terminus (1986) Nature, 320, pp. 277-280; Rosnet, O., Schiff, C., Pebusque, M.J., Human FLT3/FLK2 gene: CDNA cloning and expression in hematopoietic cells (1993) Blood, 82, pp. 1110-1119; Small, D., Levenstein, M., Kim, E., STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells (1994) Proc Natl Acad Sci U S A, 91, pp. 459-463; Broudy, V.C., Stem cell factor and hematopoiesis (1997) Blood, 90, pp. 1345-1364; Rousset, D., Agnes, F., Lachaume, P., Andre, C., Galibert, F., Molecular evolution of the genes encoding receptor tyrosine kinase with immunoglobulin-like domains (1995) J Mol Evol, 41, pp. 421-429; Ishikawa, K., Komuro, T., Hirota, S., Kitamura, Y., Ultrastructural identification of the c-kit-expressing interstitial cells in the rat stomach: A comparison of control and Ws/Ws mutant rats (1997) Cell Tissue Res, 289, pp. 137-143; Russell, E.S., Hereditary anemias of the mouse: A review for geneticists (1979) Adv Genet, 20, pp. 357-459; Nocka, K., Majumder, S., Chabot, B., Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice - Evidence for an impaired c-kit kinase in mutant mice (1989) Genes Dev, 3, pp. 816-826; Natali, P.G., Nicotra, M.R., Sures, I., Mottolese, M., Botti, C., Ullrich, A., Breast cancer is associated with loss of the c-kit oncogene product (1992) Int J Cancer, 52, pp. 713-717; Turner, A.M., Zsebo, K.M., Martin, F., Jacobsen, F.W., Bennett, L.G., Broudy, V.C., Nonhematopoietic tumor cell lines express stem cell factor and display c-kit receptors (1992) Blood, 80, pp. 374-381; Migliaccio, G., Migliaccio, A.R., Valinsky, J., Stem cell factor induces proliferation and differentiation of highly enriched murine hematopoietic cells (1991) Proc Natl Acad Sci U S A, 88, pp. 7420-7424; Dolci, S., Williams, D.E., Ernst, M.K., Requirement for mast cell growth factor for primordial germ cell survival in culture (1991) Nature, 352, pp. 809-811; Tsai, M., Shih, L.S., Newlands, G.F., The rat c-kit ligand, stem cell factor, induces the development of connective tissue-type and mucosal mast cells in vivo. Analysis by anatomical distribution, histochemistry, and protease phenotype (1991) J Exp Med, 174, pp. 125-131; Huizinga, J.D., Thuneberg, L., Kluppel, M., Malysz, J., Mikkelsen, H.B., Bernstein, A., W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity (1995) Nature, 373, pp. 347-349; Hirota, S., Isozaki, K., Moriyama, Y., Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors (1998) Science, 279, pp. 577-580; Medeiros, F., Corless, C.L., Duensing, A., KIT-negative gastrointestinal stromal tumors: Proof of concept and therapeutic implications (2004) Am J Surg Pathol, 28, pp. 889-894; Heinrich, M.C., Corless, C.L., Duensing, A., PDGFRA activating mutations in gastrointestinal stromal tumors (2003) Science, 299, pp. 708-710; Buchdunger, E., Cioffi, C.L., Law, N., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors (2000) J Pharmacol Exp Ther, 295, pp. 139-145; Druker, B.J., Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML (2002) Oncogene, 21, pp. 8541-8546; Druker, B.J., STI571 (Gleevec) as a paradigm for cancer therapy (2002) Trends Mol Med, 8, pp. S14-8; Von Mehren, M., Blanke, C.D., Joensuu, H., (2002) High Incidence of Durable Responses Induced by Imatinib Mesylate (GleevecTM) in Patients with Unresectable and Metastatic Gastrointestinal Stromal Tumors (GISTs), pp. a1608, The American Society of Clinical Oncology, editors. Orlando (FL); Heinrich, M.C., Corless, C.L., Demetri, G.D., Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor (2003) J Clin Oncol, 21, pp. 4342-4349; Debiec-Rychter, M., Dumez, H., Judson, I., Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group (2004) Eur J Cancer, 40, pp. 689-695; Mol, C.D., Dougan, D.R., Schneider, T.R., Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase (2004) J Biol Chem, 279, pp. 31655-31663; Canutescu, A.A., Shelenkov, A.A., Dunbrack Jr., R.L., A graph-theory algorithm for rapid protein side-chain prediction (2003) Protein Sci, 12, pp. 2001-2014; Huang, C.C., Couch, G.S., Pettersen, E.F., Ferrin, T.E., Chimera: An extensible molecular modeling application constructed using standard components (1996) Pacific Symposium on Biocomputing, p. 724; Fletcher, C.D., Berman, J.J., Corless, C., Diagnosis of gastrointestinal stromal tumors: A consensus approach (2002) Int J Surg Pathol, 10, pp. 81-89; Corless, C.L., Fletcher, J.A., Heinrich, M.C., Biology of gastrointestinal stromal tumors (2004) J Clin Oncol, 22, pp. 3813-3825; Lasota, J., Wozniak, A., Sarlomo-Rikala, M., Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases (2000) Am J Pathol, 157, pp. 1091-1095; Kinoshita, K., Isozaki, K., Hirota, S., c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors (2003) J Gastroenterol Hepatol, 18, pp. 147-151; Kim, T.W., Lee, H., Kang, Y.K., Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors (2004) Clin Cancer Res, 10, pp. 3076-3081; Hou, Y.Y., Tan, Y.S., Sun, M.H., C-kit gene mutation in human gastrointestinal stromal tumors (2004) World J Gastroenterol, 10, pp. 1310-1314; Demetri, G.D., Identification and treatment of chemoresistant inoperable or metastatic GIST: Experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571) (2002) Eur J Cancer, 38 (5 SUPPL.), pp. S52-9; Demetri, G.D., Von Mehren, M., Blanke, C.D., Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors (2002) N Engl J Med, 347, pp. 472-480; Eisenberg, B.L., Von Mehren, M., Pharmacotherapy of gastrointestinal stromal tumours (2003) Expert Opin Pharmacother, 4, pp. 869-874; Eisenberg, B.L., Imatinib mesylate: A molecularly targeted therapy for gastrointestinal stromal tumors (2003) Oncology, 17, pp. 1615-1620, Huntingt; Von Mehren, M., Recent advances in the management of gastrointestinal stromal tumors (2003) Curr Oncol Rep, 5, pp. 288-294; Von Mehren, M., Gastrointestinal stromal tumors: A paradigm for molecularly targeted therapy (2003) Cancer Invest, 21, pp. 553-563; Heinrich, M.C., Blanke, C.D., Druker, B.J., Corless, C.L., Inhibition of KIT tyrosine kinase activity: A novel molecular approach to the treatment of KIT-positive malignancies (2002) J Clin Oncol, 20, pp. 1692-1703; Heinrich, M.C., Rubin, B.P., Longley, B.J., Fletcher, J.A., Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations (2002) Hum Pathol, 33, pp. 484-495; Paez, J.G., Janne, P.A., Lee, J.C., EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy (2004) Science, 304, pp. 1497-1500; Sordella, R., Bell, D.W., Haber, D.A., Settleman, J., Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways (2004) Science, 305, pp. 1163-1167; Miettinen, M., Sarlomo-Rikala, M., Lasota, J., Gastrointestinal stromal tumors: Recent advances in understanding of their biology (1999) Hum Pathol, 30, pp. 1213-1220; Nishida, T., Hirota, S., Taniguchi, M., Familial gastrointestinal stromal tumours with germline mutation of the KIT gene (1998) Nat Genet, 19, pp. 323-324; Maeyama, H., Hidaka, E., Ota, H., Familial gastrointestinal stromal tumor with hyperpigmentation: Association with a germline mutation of the c-kit gene (2001) Gastroenterology, 120, pp. 210-215; Isozaki, K., Terris, B., Belghiti, J., Schiffmann, S., Hirota, S., Vanderwinden, J.M., Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors (2000) Am J Pathol, 157, pp. 1581-1585; Hirota, S., Nishida, T., Isozaki, K., Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene (2002) Gastroenterology, 122, pp. 1493-1499; Robson, M.E., Glogowski, E., Sommer, G., Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia (2004) Clin Cancer Res, 10, pp. 1250-1254; Chan, P.M., Ilangumaran, S., La Rose, J., Chakrabartty, A., Rottapel, R., Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region (2003) Mol Cell Biol, 23, pp. 3067-3078; Ma, Y., Cunningham, M.E., Wang, X., Ghosh, I., Regan, L., Longley, B.J., Inhibition of spontaneous receptor phosphorylation by residues in a putative ?-helix in the KIT intracellular juxtamembrane region (1999) J Biol Chem, 274, pp. 13399-13402; Ma, Y., Longley, B.J., Wang, X., Blount, J.L., Langley, K., Caughey, G.H., Clustering of activating mutations in c-KIT's juxtamembrane coding region in canine mast cell neoplasms (1999) J Invest Dermatol, 112, pp. 165-170; Samuels, Y., Velculescu, V.E., Oncogenic mutations of PIK3CA in human cancers (2004) Cell Cycle, 3, pp. 1221-1224; Broderick, D.K., Di, C., Parrett, T.J., Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas (2004) Cancer Res, 64, pp. 5048-5050; Bachman, K.E., Argani, P., Samuels, Y., The PIK3CA gene is mutated with high frequency in human breast cancers (2004) Cancer Biol Ther, 3, pp. 772-775; Samuels, Y., Wang, Z., Bardelli, A., High frequency of mutations of the PIK3CA gene in human cancers (2004) Science, 304, p. 554.